KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Accumulated Expenses (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Accumulated Expenses data on record, last reported at $8.6 million in Q3 2025.

  • For Q3 2025, Accumulated Expenses fell 73.42% year-over-year to $8.6 million; the TTM value through Sep 2025 reached $8.6 million, down 73.42%, while the annual FY2024 figure was $2.8 million, 49.0% down from the prior year.
  • Accumulated Expenses reached $8.6 million in Q3 2025 per NKTR's latest filing, down from $35.1 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $37.4 million in Q1 2023 and bottomed at $2.8 million in Q4 2024.
  • Average Accumulated Expenses over 5 years is $21.9 million, with a median of $24.4 million recorded in 2022.
  • Peak YoY movement for Accumulated Expenses: crashed 80.26% in 2024, then skyrocketed 323.27% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $15.7 million in 2021, then tumbled by 39.1% to $9.6 million in 2022, then tumbled by 42.05% to $5.6 million in 2023, then crashed by 49.0% to $2.8 million in 2024, then skyrocketed by 203.88% to $8.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $8.6 million in Q3 2025, $35.1 million in Q2 2025, and $31.3 million in Q1 2025.